Interpreting a QuantiFERON-Gold test result requires a nuanced understanding of the assay's limitations, as a false positive can occur due to a variety of biological and technical variables. While this interferon-gamma release assay (IGRA) is valued for its specificity, clinicians and laboratory professionals must recognize that no test is infallible. A false positive suggests an active tuberculosis (TB) infection when the disease is absent, potentially leading to unnecessary treatment and patient anxiety. This complexity arises from the intricate interplay between the immune system, prior vaccinations, and the technical execution of the laboratory procedure.
Understanding the QuantiFERON-Gold Assay
The QuantiFERON-Gold test functions by measuring the amount of interferon-gamma released by T-cells in response to specific TB antigens. Unlike the traditional tuberculin skin test (TST), which uses a purified protein derivative (PPD) to elicit a delayed-type hypersensitivity reaction, the IGRA targets antigens unique to *Mycobacterium tuberculosis*, such as ESAT-6 and CFP-10. This molecular basis is generally associated with higher specificity, particularly in populations vaccinated with Bacille Calmette-Guérin (BCG). However, the immunological pathways are complex, and disruptions at any stage—from sample collection to cytokine detection—can distort the results.
Cross-Reactivity with Non-Tuberculous Mycobacteria
Environmental and Opportunistic Mycobacteria
One of the primary biological causes of a false positive QuantiFERON-Gold result is cross-reactivity with environmental mycobacteria. While the TB-specific antigens (ESAT-6 and CFP-10) are designed to minimize this issue, certain non-tuberculous mycobacteria (NTM) share similar epitopes. Exposure to ubiquitous environmental bacteria, such as *Mycobacterium avium* complex (MAC) or *Mycobacterium abscessus*, can stimulate the immune system to produce interferon-gamma. This immunological memory confuses the assay, generating a positive signal despite the absence of *M. tuberculosis* infection.
Prior Bacille Calmette-Guérin (BCG) Vaccination Complications Although the IGRA is often promoted as a test unaffected by BCG vaccination, real-world data sometimes tells a different story. The BCG vaccine contains live, attenuated *Mycobacterium bovis*. In rare instances, the immune system retains immunological memory to antigens that overlap between the vaccine strain and the test antigens. If the vaccination was administered years prior or if the strain used in the vaccine shares genetic similarities with the detection targets, the T-cells may mount a response, leading to a false positive result. This is more likely in individuals vaccinated outside of standard national protocols. Laboratory and Pre-Analytical Errors
Although the IGRA is often promoted as a test unaffected by BCG vaccination, real-world data sometimes tells a different story. The BCG vaccine contains live, attenuated *Mycobacterium bovis*. In rare instances, the immune system retains immunological memory to antigens that overlap between the vaccine strain and the test antigens. If the vaccination was administered years prior or if the strain used in the vaccine shares genetic similarities with the detection targets, the T-cells may mount a response, leading to a false positive result. This is more likely in individuals vaccinated outside of standard national protocols.
Sample Handling and Transportation
Technical factors are a significant contributor to false outcomes, and sample integrity is paramount. The QuantiFERON-Gold test relies on measuring cytokine production over a 16 to 24-hour incubation period. If the blood sample is not processed correctly—such as delays in separating plasma, improper storage temperatures, or excessive physical agitation—the delicate immune cells may degrade or activate spontaneously. A compromised sample can release cytokines independent of the specific TB antigens, triggering a false positive reading long before the result reaches the clinician.
Contamination and Reagent Quality
Laboratory contamination is a critical but often overlooked variable. Carryover contamination from previous positive samples, particularly involving DNA or proteins, can introduce foreign biological material into the assay wells. Similarly, issues with the proprietary reagents—such as the antigen peptides or the capture antibodies—can lead to non-specific binding. If the coating antibodies or the detection antibodies malfunction, they might stick to the well walls or interact with other proteins in the blood, generating a signal that mimics the presence of TB DNA.
